Pancreatic Exocrine Insufficiency clinical trials

Explore recruiting pancreatic exocrine insufficiency clinical trials.

Recruiting pancreatic exocrine insufficiency studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Pancreatic Exocrine Insufficiency trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An open-label, multicenter, prospective, single-arm, exploratory study to assess role of pancreatic enzyme replacement therapy (PERT) (Creon® 25,000) in patients with Pancreatic Exocrine Insufficiency (PEI) after total gastrectomy.

Portugal, Poland, Spain

Therapeutic use (Phase IV) EU CTIS Study details

An Open-Label, Multicenter, Prospective, Interventional Study to Assess the Role of Pancreatic Enzyme Replacement Therapy (PERT) (Creon® 35,000) in Patients with Pancreatic Exocrine Insufficiency (PEI) after Pancreatic Surgery

Germany, Poland, Spain, Austria

Therapeutic confirmatory (Phase III) EU CTIS Study details

Open label randomized, multicentre, controlled trial of pancreatic enzyme replacement therapy (PERT) for pancreatic exocrine insufficiency (PEI) in patients with unresectable pancreatic cancer.

Spain, France, Italy, Sweden

Therapeutic use (Phase IV) EU CTIS Study details

A Phase 2a, Randomized, Open-Label, Active-Controlled, Crossover Study to Evaluate Safety and Explore Efficacy of Different Doses of New Lipase NHS7108 Administered Orally in Participants with Exocrine Pancreatic Insufficiency.

Poland, Hungary, Spain, Bulgaria, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Open-label single-arm, multicenter clinical trial to evaluate patient acceptability of a new CREON formulation of Pancreas Powder gastro-resistant pellets in patients with cystic fibrosis suffering from pancreatic exocrine insufficiency.

Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

Pancreatic Exocrine Insufficiency trials by city

Pancreatic Exocrine Insufficiency in Toronto Pancreatic Exocrine Insufficiency in Vancouver Pancreatic Exocrine Insufficiency in Montreal Pancreatic Exocrine Insufficiency in Calgary Pancreatic Exocrine Insufficiency in Edmonton Pancreatic Exocrine Insufficiency in Ottawa Pancreatic Exocrine Insufficiency in Winnipeg Pancreatic Exocrine Insufficiency in Quebec City Pancreatic Exocrine Insufficiency in Hamilton Pancreatic Exocrine Insufficiency in Kitchener Pancreatic Exocrine Insufficiency in London Pancreatic Exocrine Insufficiency in Halifax Pancreatic Exocrine Insufficiency in New York Pancreatic Exocrine Insufficiency in Los Angeles Pancreatic Exocrine Insufficiency in Chicago Pancreatic Exocrine Insufficiency in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease